Related Experiment Video
Updated: Jun 17, 2026
06:34
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
Hurdles and leaps for protein therapeutics
Steven Kozlowski1, Barry Cherney, Raymond P Donnelly
1Office of Biotechnology Products, Office of Pharmaceutical Science, Center for Drug Evaluation and Research, U.S. FDA, Silver Spring, Maryland 20993, USA. steven.kozlowski@fda.hhs.gov
Annals of the New York Academy of Sciences
|January 16, 2010
Summary
Cytokine therapeutics, proteins modulating inflammation, show promise but face clinical development challenges. Past successes and failures inform future strategies for these potent biological molecules.
Area of Science:
- Immunology and protein therapeutics
- Biochemistry of cellular signaling
Background:
- Cytokines are diverse proteins regulating cellular activities, including critical roles in inflammatory responses.
- Inflammatory cytokines are key targets for protein drug development due to their potent biological activities.
- The development of cytokine therapeutics has encountered both significant successes and notable failures.
Purpose of the Study:
- To review the history and challenges of cytokine therapeutics.
- To consider strategies for future development of cytokine-based drugs.
Main Methods:
- Historical analysis of cytokine therapeutic development.
- Review of past successes and failures in clinical trials.
- Consideration of manufacturing and clinical development hurdles.
Main Results:
- Initial challenges in manufacturing capacity for cytokines have been largely resolved.
- Clinical development of cytokine therapeutics continues to present significant challenges.
- Past experiences provide valuable insights into overcoming current obstacles.
Conclusions:
- Despite manufacturing advancements, clinical development remains a critical hurdle for cytokine therapeutics.
- A historical perspective is essential for devising effective future strategies in cytokine drug development.
- Further research and strategic planning are needed to realize the full therapeutic potential of cytokines.
Related Concept Videos
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:27Upstream Processing
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
01:12Protein Absorption
Proteins in the gastrointestinal tract typically come from food, but they can also originate from disintegrated cells or secreted enzymes. In the stomach, the enzyme pepsin breaks down these proteins into polypeptides. The fragments then move into the duodenum as a semi-fluid mass called chyme. Pancreatic proteases, such as trypsin and chymotrypsin, and intestinal brush border enzymes like carboxypeptidases further dismantle the polypeptides into tripeptides, dipeptides, and free amino acids.
01:28Proteins: Dietary Sources and Requirements
Consuming animal-based products offers high-quality proteins that contain optimal levels and combinations of essential amino acids, crucial for tissue repair and growth. Foods like eggs, milk, fish, and most meats are a source of complete proteins. Legumes and cereals are abundant in proteins; however, they typically lack a full range of essential amino acids. As a result, they are considered incomplete protein sources. Some plant sources like soybeans, quinoa, and amaranth do contain complete...
01:22Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...